Amyloid Protein Blockers:拮抗薬のグローバル市場2014(薬開発、治験動向)

◆英語タイトル:Amyloid Protein Blockers -Pipeline Insights, 2014
◆発行会社/調査会社:DelveInsight
◆商品コード:DIMR201479
◆発行日:2014年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥137,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Amyloid Protein Blockers:拮抗薬のグローバル市場2014(薬開発、治験動向)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DelveInsight’s,“Amyloid Protein Blockers-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Amyloid Protein Blockers. This report provides information on the therapeutic development based on the Amyloid Protein Blockers dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of Amyloid Protein Blockers
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Amyloid Protein Blockers pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Amyloid Protein Blockers and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

• Complete MOA intelligence and complete understanding over therapeutics development for Amyloid Protein Blockers
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Amyloid Protein Blockers pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

*** レポート目次(コンテンツ)***

• Amyloid Protein Blockers Overview
• Amyloid Protein Blockers Disease Associated
• Amyloid Protein Blockers Pipeline Therapeutics
• Amyloid Protein Blockers Therapeutics under Development by Companies
• Amyloid Protein Blockers Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Amyloid Protein Blockers Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Amyloid Protein Blockers Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Amyloid Protein Blockers Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Amyloid Protein Blockers – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Amyloid Protein Blockers – Discontinued Products
• Amyloid Protein Blockers – Dormant Products
• Companies Involved in Therapeutics Development for Amyloid Protein Blockers
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Amyloid Protein Blockers by Therapy Area, 2014
• Number of Products under Development for Amyloid Protein Blockers, 2014
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
• Drug Candidates Profiles
• Amyloid Protein Blockers Assessment by Monotherapy Products
• Amyloid Protein Blockers Assessment by Combination Products
• Amyloid Protein Blockers Assessment by Route of Administration
• Amyloid Protein Blockers Assessment by Stage and Route of Administration
• Amyloid Protein Blockers Assessment by Molecule Type
• Amyloid Protein Blockers Assessment by Stage and Molecule Type
• Amyloid Protein Blockers Therapeutics – Discontinued Products
• Amyloid Protein Blockers Therapeutics – Dormant Products
• Products under Development by Companies, 2014

• Number of Products under Development for Amyloid Protein Blockers by Therapy Area, 2014
• Number of Products under Development for Amyloid Protein Blockers, 2014
• Late Clinical Stage Products (Filed and Phase III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Amyloid Protein Blockers Assessment by Monotherapy Products
• Amyloid Protein Blockers Assessment by Combination Products
• Amyloid Protein Blockers Assessment by Route of Administration
• Amyloid Protein Blockers Assessment by Stage and Route of Administration
• Amyloid Protein Blockers Assessment by Molecule Type
• Amyloid Protein Blockers Assessment by Stage and Molecule Type

*** レポートのキーワード ***

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIMR201479 )"Amyloid Protein Blockers:拮抗薬のグローバル市場2014(薬開発、治験動向)" (英文:Amyloid Protein Blockers -Pipeline Insights, 2014)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。